Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib +/ onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit
Am J Physiology-Gastrointestinal Liver Physiol 298:G248G254 van Meer L, Moerland M, Cohen AF, Burggraaf J (2014) Urinary kidney biomarkers for early detection of nephrotoxicity in clinical drug development
Everyone Responds Differently The timeline varies from patient to patient based on individual biology, health status, and lifestyle factors
Melatonin: What You Need To Know
Guy starts testosterone therapy, and suddenly he's getting more attention
The Effect of Folate Fortification on Folic Acid-Based Homocysteine-Lowering Intervention and Stroke Risk: A Meta-Analysis. Public Health Nutrition, vol